VIR - NASDAQ

Vir Biotechnology, Inc.

Vir Biotechnology, Inc.

VIRยทNASDAQ

$8.77

+0.34%
HealthcareBiotechnology

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$1.48B
EPS-3.1600
P/E Ratio-2.78
Earnings Date08/05/2026
Vir Biotechnology, Inc.

Vir Biotechnology, Inc. Fair Value Envelope

VIR ยท NASDAQ

Our analysis suggests that VIR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $8.77, this represents a potential HIDDEN relative to our calculated worth for Vir Biotechnology, Inc..

HIDDEN
Intrinsic Value
Current Price: $8.77

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$5.0B
+ Cash & Equivalents$234.1M
Firm Value-$4.7B
- Debt$186.9M
Equity Value-$4.9B
/ Shares Outstanding139,113,702B
DCF Value-$35
OVERVALUED BY 503%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$441.0M
-$496.5M
-$558.9M
-$629.2M
-$708.3M
-$797.4M
-$897.6M
-$1.0B
-$1.1B
-$1.3B
Maintenance CapEx
-$1.1M
-$1.2M
-$1.4M
-$1.6M
-$1.7M
-$2.0M
-$2.2M
-$2.5M
-$2.8M
-$3.2M
Owner Earnings
-$442.1M
-$497.7M
-$560.3M
-$630.8M
-$710.1M
-$799.3M
-$899.8M
-$1.0B
-$1.1B
-$1.3B
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$409.4M
-$426.7M
-$444.8M
-$463.6M
-$483.3M
-$503.7M
-$525.0M
-$547.3M
-$570.5M
-$594.6M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your VIR research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.